Skip to main content
Delfa

← All trials/NCT02674893

GLP1 et Goût

TerminatedPhase 4

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

Comparative Study of Gustatory Performance, Sensory Specific Satiation, Liking and Wanting in Patients With Type 2 Diabetes

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

48

Study population

Healthy volunteers, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥27•HbA1c ≥7%•Healthy volunteers

Primary endpoint

•Modifications in wanting

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02674893
Org study IDBRINDISI 2013

Timeline

Milestones

Study start2014-02-04actual
Study first posted2016-02-05estimated
Primary completion2016-08-31actual
Study completion2016-08-31actual
Last update posted2026-02-09actual

Assets

Investigational agents

Liraglutide

Who this study enrolls

Healthy volunteersObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE

•persons who have provided written informed consent
•aged > 18 years
•type 2 diabetes with HbA1C > 7%
•overweight (BMI > 27)
•normal renal function (creatinine clearance > 50ml/min)
•patients to be treated with Liraglutide (patients with type 2 diabetes with HbA1C > 7.5% and overweight or obesity, whose current treatment is insufficient to control the diabetes).

CONTROL DIABETIC PATIENTS

•persons who have provided written informed consent
•aged > 18 years
•type 2 diabetes with HbA1C > 7%
•overweight (BMI > 27)
•patients for whom treatment with Liraglutide is not indicated
•normal renal function (creatinine clearance > 50ml/min)

HEALTHY SUBJECTS

•persons who have provided written informed consent
•aged > 18 years

Exclusion criteria

DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE

•type 1 diabetes
•decompensated congestive heart failure
•acute or chronic infection, progressive cancer, liver cirrhosis
•ongoing treatment with antibiotics
•smoking
•chronic alcohol abuse (>4 glasses a day)
•aversion to the products to be eaten or smelled
•poor understanding of the cognitive tasks requested
•treatment interfering with olfactogustatory performance, such as psychotropic, anti-emetic and anti-ulcer drugs
•persons without national health insurance cover
•persons under guardianship
•hypersensitivity to Liraglutide
•pregnancy, breastfeeding
•history of acute or chronic pancreatitis
•calcitonin level at selection ≥ 50 ng/L
•liver disease, defined by a level of alanine aminotransferase (ALAT) ≥ 2.5 times the upper limit of normal (ULN) for reference values

CONTROL DIABETIC PATIENTS

•type 1 diabetes,
•decompensated congestive heart failure,
•acute or chronic infection, progressive cancer, liver cirrhosis,
•ongoing treatment with antibiotics,
•smoking
•chronic alcohol abuse (> 4 glasses a day),
•aversion to the products to be eaten or smelled,
•poor understanding of the cognitive tasks requested,
•treatment interfering with olfactogustatory performance, such as psychotropic, anti-emetic and anti-ulcer drugs.
•persons without national health insurance cover
•persons under guardianship

HEALTHY SUBJECTS

•diabetes (type I and II)
•sensory disorders
•decompensated congestive heart failure,
•acute or chronic infection, progressive cancer, liver cirrhosis,
•ongoing treatment with antibiotics,
•smoking
•chronic alcohol abuse (> 4 glasses a day),
•aversion to the products to be eaten or smelled,
•poor understanding of the cognitive tasks requested,
•treatment interfering with olfactogustatory performance (psychotropic, anti-emetic, anti-ulcer drugs)
•persons without national health insurance cover
•persons under guardianship
•contra-indications to MRI, notably, but not limited to: pace maker, implantable cardiac defibrillators, neurostimulators, cochlear implants, certain implanted automated injection systems (insulin pumps), vascular intracerebral ferromagnetic clips, certain systems to regulate intravascular temperature, myopia requiring the patients to wear spectacle, history of stroke or transient ischemic attack (TIA), metallic foreign body, in particular intraocular or situated near high-risk zones (nervous system, vascular system), claustrophobia….

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
4
Weight & body composition
1
Patient-reported / QoL
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint/low confidence

Anthropometric modifications

Time frame:Until 3 months

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint/low confidence

Modifications in wanting

Time frame:Up to 3 months

change from baseline, improvement

Other clinical outcomes

4 endpoints
Secondary/protocol endpoint/low confidence

Modifications in gustatory performance

Time frame:Until 3 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Modifications in liking

Time frame:Until 3 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Modifications in salivation following the presentation of foods

Time frame:Until 3 months

change from baseline, descriptive

Secondary/protocol endpoint

Modifications in optimal preferences for sweet and fatty tastes

Time frame:Until 3 months

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.